Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms

Authors


Gert J. Ossenkoppele, Department of Haematology, Cancer Centre Amsterdam, VU Institute for Cancer and Immunology, VU University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
E-mail: g.ossenkoppele@vumc.nl

Summary

This article reviews the use of aberrant antigen expression detected by flow cytometry in the diagnosis and clinical handling of acute myeloid leukaemia (AML) and the myelodysplastic syndromes (MDS). Such aberrancies offer a valuable tool for the proper classification of these myeloid malignancies according the World Health Organization 2008 classification. Aberrant antigen expression by flow cytometry is also important for prognostification. This review supports the view, that minimal residual disease detection methods that make use of such aberrancies should be part of the routine management of AML patients to guide therapy, but also suggests the introduction of flow cytometry in MDS for diagnosis and treatment decisions in the near future.

Ancillary